ClinicalTrials.gg
CompletedNCT03476018Updated Jun 16, 2022

Trial to Optimally Show the Pharmacological Action of Z-100

A Phase 3 interventional study of Z-100 and Placebos in Cervical Cancer, sponsored by Zeria Pharmaceutical. Completed at 2 sites in Vietnam. Open to female participants aged 21 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-06-16.

Sponsored by Zeria Pharmaceutical · Phase 3, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
21 Years to 79 Years
Sex
Female
01

Study summary

The objective of this clinical trial is to evaluate the change of the immunological parameter levels in FIGO stage IIIB cervical cancer subjects by administration of Z-100

02

Conditions studied

  • Cervical Cancer
03

In context

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

This study's enrollment of 72 is below the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Zeria Pharmaceutical is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 79 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. FIGO stage (2008): IIIB, cervical cancer
  2. confirmed squamous cell carcinoma of the cervix
  3. Subjects with treatment-naive cervical cancer
  4. Subjects without enlargement (≥15 mm in the short axis) in the lower abdominal para-aortic lymph node
  5. Subjects ≥21, ≤79 years of age at
  6. Subjects for whom it is considered possible to carry out intracavitary radiation in radiotherapy
  7. Subjects for whom it is considered possible to carry out concurrent cisplatin treatment with radiotherapy
  8. Performance Status: 0-2
  9. Subjects with the following organ functions; (1) WBC ≥3,000/mm3 (2) count ≥100,000/mm3 (3) ≥9.5 g/dL (correction by medication, e.g. blood transfusion, iron compounds, is allowed) (4) Total ≤ three (3) times the upper limit of reference value at the clinical testing laboratory (5) , ALT ≤ three (3) times the upper limit of reference value at the clinical testing laboratory (6) : ≥50 mL/min
  10. Subjects who are willing to give informed consent

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a double cancer or are being treated for that
  2. Subjects who have suffered from cancers other than cervical cancer within 5 years prior to obtaining consent
  3. Subjects with cancer of the cervical stump which is judged by the investigator
  4. Subjects who have a history of being diagnosed of disease
  5. Subjects who have a history of radiotherapy in the pelvis
  6. Subjects who have a history of to cisplatin or other medical agents which contain platinum
  7. Subjects complicated with a serious drug allergy
  8. Subjects with a serious complication (poorly controlled hypertension, haemorrhagic tendency, connective tissue disease being treated with )
  9. Pregnant women, nursing mothers or subjects who desire pregnancy during the trial period
  10. Subjects who have ongoing infection of (HIV), active virus (HBV), virus (HCV)
  11. Subjects with symptomatic tuberculosis at the date of obtaining consent
  12. Subjects who have received any other medicinal products or medical devices within 28 days prior to obtaining consent
  13. Other subjects considered inappropriate to participate in the trial by the investigator
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebos

  • Experimental
    0.2 microgram Z-100

    Drug: Z-100

  • Experimental
    2 microgram Z-100

    Drug: Z-100

  • Experimental
    20 microgram Z-100

    Drug: Z-100

Interventions

  • DrugZ-100

    Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days

  • DrugPlacebos

    Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days

06

What researchers measure

Primary outcomes

  1. Change in the number of immunological cells

    Time frame: 2 years

Secondary outcomes

  1. Overall survival

    Time frame: 3 years

  2. Disease-specific survival

    Time frame: 2 years

  3. Recurrence-free survival

    Time frame: 3 years

  4. Rate of adverse events/adverse drug reactions

    Time frame: 2 years

07

Study locations

2 sites
  • Zeria Investrigative Sites
    Hanoi, Vietnam
  • Zeria Investigative sites
    Ho Chi Minh City, Vietnam
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jul 2021, 39 months.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 39 months is above that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2018
First posted
Mar 23, 2018
StartActual
Apr 2, 2018
Primary completionActual
Jul 20, 2021
CompletionActual
Dec 10, 2021
Last update
Jun 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03476018
Responsible party
Sponsor
First posted
Mar 23, 2018
Start date
Apr 2, 2018
Primary completion
Jul 20, 2021
Completion
Dec 10, 2021
Last update
Jun 16, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Specific substance maruyama

Start the discussion